Stocks and Investing
Stocks and Investing
Fri, December 8, 2023
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
Michael Yee Downgraded (BEAM) to Hold and Decreased Target to $30 on, Dec 8th, 2023
Michael Yee of Jefferies, Downgraded "Beam Therapeutics Inc." (BEAM) to Hold and Decreased Target from $75 to $30 on, Dec 8th, 2023.
Michael has made no other calls on BEAM in the last 4 months.
There are 4 other peers that have a rating on BEAM. Out of the 4 peers that are also analyzing BEAM, 2 agree with Michael's Rating of Hold. Following are those relevant analyst calls for the last 4 months
- Gena Wang of "Barclays" Maintained at Hold with Decreased Target to $35 on, Wednesday, August 9th, 2023
- Richard Law of "Credit Suisse" Maintained at Hold with Increased Target to $47 on, Wednesday, August 9th, 2023
These are the ratings of the 2 analyists that currently disagree with Michael
- Rick Bienkowski of "Cantor Fitzgerald" Maintained at Buy with Decreased Target to $32 on, Tuesday, October 17th, 2023
- Samantha Semenkow of "Citigroup" Maintained at Strong Buy with Decreased Target to $56 on, Wednesday, August 9th, 2023
Contributing Sources